Skip to main content

Advertisement

SpringerLink
Log in

Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to analyze prognostic factors and evaluate the value of four prognostic scores including RPA, DS-GPA BS-BM, GGS for the EGFR mutant BM patients from lung adenocarcinoma treated with EGFR-TKI. Data of NSCLC were retrospectively reviewed from August 2010 to June 2015 using the medical database of Shanxi Provincial Cancer Hospital. Patients with BM from lung adenocarcinoma with mutant EGFR treated by EGFR-TKI or a combination of EGFR-TKI and WBRT were included. Potential prognostic factors were statistically examined. The C-index of each prognostic score was calculated. A total of 1063 BM patients with lung adenocarcinoma that had been identified with EGFR mutations were reviewed. A total of 104 patients that had been diagnosed with BM were confirmed to have mutant EGFR in primary tumors. These patients received treatment with EGFR-TKI or EGFR-TKI with WBRT to BM. The potential predictive factors in multivariable analysis included KPS (70 vs.70–80 vs. 90–100) and number of brain metastatic lesions. In the log-rank test, the indexes of RPA, DS-GPA BS-BM, and GGS were all significant predictors of OS. The C-indexes of each prognostic score were 0.79, 0.76, 0.77, and 0.74 in DS-GPA, RPA, GGS, and BS-BM, respectively. The indexes of RPA, DS-GPA BS-BM, GGS were applicable for asessing survival stratification in brain metastases from lung adenocarcinoma with presented EGFR mutations in our independent population. The DS-GPA appears to be the best predictive value. However, all four of the indexes could not evaluate the exact independent prognostic factors in multivariable analysis. A prognostic index specific for this group of patients was needed for targeted lung cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872

    Article  PubMed  Google Scholar 

  2. Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48–54

    Article  PubMed  Google Scholar 

  3. Ding X, Dai HH, Hui ZG, Ji W, Liang J, Lv J et al (2012) Risk factors of brain metastases in completely resected pathological stageIIIA-N2non-smallcell lung cancer. Radiat Oncol 7:119

    Article  PubMed  PubMed Central  Google Scholar 

  4. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94:2698–2705

    Article  PubMed  Google Scholar 

  5. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors 316 in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751

    Article  CAS  PubMed  Google Scholar 

  6. Lorenzoni J, Devriendt D, Massager N et al (2004) Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 60:218–224

    Article  PubMed  Google Scholar 

  7. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514

    Article  PubMed  Google Scholar 

  8. Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:655–661

    Article  PubMed  Google Scholar 

  9. Cairncross JG, Kim JH, Posner JB (1980) Radiation therapy for brain metastases. Ann Neurol 7:529–541

    Article  CAS  PubMed  Google Scholar 

  10. Noel G, Medioni J, Valery CA, Boisserie G, Simon JM, Cornu P et al (2003) Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. Lung Cancer 41:333–343

    Article  PubMed  Google Scholar 

  11. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int J Radiat Oncol Biol Phys 47:291–298

    Article  CAS  PubMed  Google Scholar 

  12. Fokas E, Henzel M, Surber G, Kleinert G, Hamm K, Engenhart-Cabillic R (2012 Aug) Stereotactic radiosurgery and fractionated stereotactic radiotherapy: comparison of efficacy and toxicity in 260 patients with brain metastases. J Neurooncol 109(1):91–98

    Article  PubMed  Google Scholar 

  13. Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang, Prospective A (2014 Feb) Molecular epidemiology study of egfr mutations in asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2):154–162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li Z, Guo H (2011) The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J Clin Oncol 29:e18065

    Article  Google Scholar 

  15. Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57:359–364

    Article  PubMed  Google Scholar 

  16. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65:351–354

    Article  PubMed  Google Scholar 

  17. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, Huang YS, Yan HH, Ren S, Liu Y, Yang JJ (2013) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 24(4):993–999

    Article  PubMed  Google Scholar 

  18. R Core Team (2013). R Foundation for Statistical Computing, Vienna

  19. Golden DW, Lamborn KR, McDermott MW, Kunwar S, Wara WM, Nakamura JL, Sneed PK (2008) Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg. 109:77–86

  20. Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V, Salinas P, Catot S, Isla D, Pradas A, Gúrpide A, de Castro J, Polo E, Puig T, Tarón M, Colomer R (2011) Rosell RBrain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 37(3):624–631

    Article  CAS  PubMed  Google Scholar 

  21. Venur VA, Ahluwalia MS (2016) Targeted therapy in brain metastases: ready for primetime? Am Soc Clin Oncol Educ Book 35:e123–e130

    Article  PubMed  Google Scholar 

  22. Soffietti R, Trevisan E, Rudà R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24(6):679–686

    Article  CAS  PubMed  Google Scholar 

  23. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin N, Mehta M (2012) The Effect of tumor subtype on survival and the graded prognostic assessment (gpa) for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82(5):2111–2117

    Article  PubMed  Google Scholar 

  24. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JPS, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 30(4): 419–425

    Article  PubMed  Google Scholar 

  25. Wilkins A, Furness A, Corbett RW Bloomfield A, Porta N, Morris S, Ali Z, Larkin J, Harrington K (2015) The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. Br J Cancer 113(9):1275–1281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Byeon S, Ham JS, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2016) Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol 33(8):97

    Article  PubMed  PubMed Central  Google Scholar 

  27. Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, Zhang J EGFR (2016) TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases. J Thorac Oncol 11(10):1718–1728

    Article  PubMed  Google Scholar 

  28. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923–929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kun-Ming Rau, Han-Ku Chen, Li-Yen Shiu, Tsai-Ling Chao, Yi-Ping Lo, Chin-Chou Wang, Meng-Chih Lin (2016) Chao-cheng huang discordance of mutation statuses of epidermal growth factor receptor and K-ras between primary adenocarcinoma of lung and brain metastasis. Int J Mol Sci 17(4):524

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wang S, Wang Z (2015) Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer. Clin Oncol (R Coll Radiol) 27(1):30–39

    Article  CAS  Google Scholar 

  31. Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, Tondat F, Inghirami G, Sapino A, Scagliotti GV, Papotti M, Novello S (2009) Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol 4(6):684–688

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank LetPub (http://www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, 030013, People’s Republic of China

    Hongwei Li, Weili Wang, Jianzhong Cao, Xiaqin Zhang, Xin Song, Sufang Jia, Haixia Jia & Shengmin Lan

  2. Department of Surgery, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, 030013, People’s Republic of China

    Jianhong Lian

  3. Department of Chemotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, 030013, People’s Republic of China

    Songyan Han & Weihua Yang

  4. Department of Pathology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, 030013, People’s Republic of China

    Hongxing Jin & Yanfeng Xi

  5. Department of Medical Imageology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, 030013, People’s Republic of China

    Hongxing Jin & Jiwei Ren

Authors
  1. Hongwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianhong Lian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongxing Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weili Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianzhong Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaqin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xin Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sufang Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Haixia Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiwei Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Songyan Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Weihua Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yanfeng Xi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shengmin Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hongwei Li or Hongxing Jin.

Ethics declarations

Conflict of interest

The Authors declare that they have no conflict of interest.

Research involved in human and animal participants

This article does not contain any studies with human participants performed by any of the authors.

Additional information

Hongwei Li and Jianhong Lian have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Lian, J., Jin, H. et al. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations. J Neurooncol 133, 129–135 (2017). https://doi.org/10.1007/s11060-017-2411-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2411-2

Keywords

Search

Navigation